Imagion Biosystems Ltd. has released a press release.
IBX Secures Firm Commitments for $3.75m for Clinical Trial
Earlier from Imagion Biosystems
- Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
- Imagion Biosystems Receives IND Clearance from US FDA
- Appendix 4C and Quarterly Activities Report - March 2026
- FY25 Appendix 4E and Annual Report